Search Results
Jan 08, 2026, 14:00 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
weight-related medical problems to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and
More news about: Eli Lilly and Company
Dec 30, 2025, 14:27 ET Eksoottisten lemmikkieläinten kaupan hallitseminen ekologisten ja sosiaalisten riskien vähentämiseksi
Hispaniolan jättiläisliskon ja muiden eläinten luokittelu ylöspäin liitteestä II liitteeseen I.Suuri osa eksoottisten lemmikkieläinten kaupasta liittyy yhä enemmän salametsästykseen ja salakuljetukseen. Suuripäinen kilpikonna (Platysternon megacephalum),
More news about: WWF China
Dec 22, 2025, 13:00 ET Dr. Stephen H. Sheldon Receives National Sleep Foundation's Lifetime Achievement Award
Medicine. Dr. Sheldon served on NSF's board of directors from 2013 to 2020, chairing its Education and CME Committees. He also designed NSF's pediatric OSA anatomical model and was instrumental in the development of NSF's Adolescent Sleep Health Recommendations (currently pending publication).Learn
More news about: National Sleep Foundation
Dec 18, 2025, 06:45 ET Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
weight-related medical problems to lose excess body weight and keep the weight off.moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.It should be used with a reduced-calorie diet and increased physical activity.Zepbound contains tirzepatide and
More news about: Eli Lilly and Company
Dec 17, 2025, 19:00 ET Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
in Chinese participants with overweight/obesity and metabolic dysfunction-associated fatty liver disease (MAFLD).GLORY-OSA: A Phase 3 trial in Chinese participants with OSA and obesity.Among these, the first five phase 3 studies have met primary endpoints, and the latter two phase
More news about: Innovent Biologics
Dec 16, 2025, 10:00 ET Brandwatch nimettiin johtavaksi sosiaalisen median hallinnoinnissa ja merkittäväksi toimijaksi influencer-markkinoinnissa uusissa 2025 analyytikoraportteissa
tarjoavat teknologian ostajille myös 360 asteen arvioinnin nykyisten ja tulevien tarjoajien vahvuuksista ja heikkouksista.Brandwatch on osa Cisionin brändiperhettä yhdessä CisionOnen ja PR Newswiren kanssa.Median yhteystiedot: Cision Public Relations
More news about: Brandwatch Ltd.
Dec 11, 2025, 19:00 ET Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
in Chinese adults with overweight or obesity and metabolic dysfunction-associated fatty liver disease (MAFLD);GLORY-OSA: in Chinese adults with obstructive sleep apnea (OSA) and obesity.Among these, the first five Phase 3 clinical studies have met their primary endpoints, while the
More news about: Innovent Biologics
Dec 02, 2025, 22:30 ET SCゼウス、日本第1号データセンター「Zeus OSA1」を大阪で着工
Zeus OSA1 は、約4,000坪（13,957㎡）の準工業地域に位置し、大阪中心部の IX や主要データセンター群へのアクセスに優れた立地に開発されます。この立地特性を生かし、増大する AI・クラウド需要に対応する西日本の主要デジタルインフラ拠点となることが期待されています。 AIワークロードの高度化に伴い、Zeus OSA1 は液冷（Direct-to-Chipを含む）に完全対応した冷却アーキテクチャを採用し、ラック当たり最大130kWの高電力密度に対応します。また、PUE
More news about: SC Zeus Data Centers Pte Ltd
Dec 02, 2025, 17:31 ET Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options | DelveInsight
in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key OSA companies, including Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific
More news about: DelveInsight Business Research, LLP
Nov 25, 2025, 19:39 ET VINNO präsentiert auf der MEDICA 2025 die Integration von „Sound, Licht und Luft" - Weltpremiere der Vicyto-Endoskopie-Serie
SchlaftherapieErstmals vorgestellt wurde die Stream-Serie CPAP von VINNO, die sich auf eine sicherere und komfortablere Schlaftherapie bei obstruktiver Schlafapnoe (OSA) konzentriert. Sie verfügt über eine FOAMLESS-Geräuschreduzierungsstruktur, die die mit der Zersetzung von Schaumstoff verbundenen Risiken beseitigt
More news about: VINNO
Nov 25, 2025, 04:00 ET Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population
Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD);GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity.Among these, the first five Phase 3 clinical studies have all met their primary endpoints,
More news about: Innovent Biologics
Nov 20, 2025, 15:35 ET Brandwatch vahvistaa johtavaa asemaansa tekoälyn alalla syvällisemmällä tiedolla ja laajemmalla datan kattavuudella
brändit ja virastot voivat toteuttaa datapohjaisia strategioita laajassa mittakaavassa. Brandwatch on osa Cisionin brändiperhettä yhdessä CisionOnen ja PR Newswiren kanssa. Mediatiedustelut, ota yhteyttä: Cision
More news about: Cision Ltd.
Nov 20, 2025, 15:16 ET Conservation X Labs and Meta Launch Landmark Dataset to Transform AI for Conservation
outline, and track objects in every frame of video, the dataset provides a foundational resource for researchers and developers. Videos were contributed by Osa Conservation in Costa Rica, the Los Amigos Biological Station in Peru, and partners in Central Africa, among others. "I'm very
More news about: Conservation X Labs
Nov 19, 2025, 19:00 ET Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD); GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity; Among these, the first five Phase 3 clinical studies
More news about: Innovent Biologics
Nov 17, 2025, 06:10 ET Undiagnosed Sleep Apnea Is Compromising the Health of 30 Million Americans -- GEM SLEEP Launches Nationwide Campaign to Help People Sleep Better and Prevent Long-Term Health Risks
have it. OSA is a silent disruptor that drains energy, slows metabolism, strains the heart and clouds focus. It happens when the airway collapses repeatedly during sleep, causing dangerous drops in oxygen levels and multiple wake-ups that fragment rest night after night. "OSA is the
More news about: GEM SLEEP
Nov 10, 2025, 09:12 ET Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'
problems to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity.
More news about: Eli Lilly and Company
Nov 10, 2025, 08:00 ET Apnimed to Participate in the LifeSci Capital & Sofinnova Partners Growth and Innovation Summit
diseases. We believe the introduction of simple, once-nightly oral drugs may dramatically expand diagnosis and the reach of treatment for people with OSA. OSA, like other common chronic diseases such as diabetes or hypertension, would benefit from having multiple drugs with differing mechanisms to more fully
More news about: Apnimed, Inc.
Nov 06, 2025, 13:54 ET Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
problems to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity.
More news about: Eli Lilly and Company
Nov 04, 2025, 16:01 ET AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
obesity. MARITIME-OSA-1, a Phase 3 study of MariTide, was recently initiated in adults living with obstructive sleep apnea on positive airway pressure therapy and living with obesity or overweight. MARITIME-OSA-2, a Phase 3 study of MariTide, was recently
More news about: Amgen
Nov 04, 2025, 06:10 ET GEM SLEEP Enhances Virtual Sleep Apnea Care with Smarter Tools for an Improved Patient Experience
In the U.S., more than 30 million people live with obstructive sleep apnea (OSA), according to the American Medical Association. Men are more likely to have it than women, and prevalence rises with age. Untreated OSA doesn't just mean loud nights and daytime grogginess, it significantly raises the
More news about: GEM SLEEP
Nov 03, 2025, 09:00 ET Apnimed Announces Publication in The Lancet of Positive Phase 2 Results Demonstrating Sulthiame's Efficacy in Obstructive Sleep Apnea
million people in the United States and nearly one billion people worldwide suffer from OSA. Up to 80% of people living with OSA are undiagnosed and therefore untreated. An individual with OSA can experience hundreds of sleep apnea events in a single night, each one reducing the
More news about: Apnimed, Inc.
Oct 29, 2025, 07:00 ET LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
have weight-related medical problems to lose excess body weight and keep the weight off, moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used
More news about: Eli Lilly and Company
Oct 27, 2025, 13:00 ET Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea
you. I'm here to say don't ignore moderate-to-severe OSA symptoms – talk to your doctor." Symptoms and Impacts: Why Addressing Moderate-to-Severe OSA Matters People with moderate-to-severe OSA may not get the necessary oxygen due to an airway that
More news about: Eli Lilly and Company
Oct 26, 2025, 20:00 ET Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD); GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity; DREAMS-1: A Phase 3 clinical study conducted in Chinese adults with
More news about: Innovent Biologics
Oct 17, 2025, 08:00 ET Apnimed To Present Additional Phase 3 Data for AD109, an Investigational Oral Pill for Obstructive Sleep Apnea, at CHEST 2025 Annual Meeting
investigational oral pill, addresses the neuromuscular root cause of OSA and the associated oxygenation deficits- Findings build upon previously reported positive topline data and further validate AD109's potential to transform OSA treatment as Apnimed prepares for a planned New Drug Application
More news about: Apnimed, Inc.